Meijing Liu
Changhongjie, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Journal: Cell transplantation
Published: March 07, 2023
Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Journal: Annals of hematology
Published: January 31, 2023
Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: February 11, 2022
Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.
Journal: Hematological oncology
Published: August 27, 2021
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Journal: Frontiers in immunology
Published: June 04, 2021
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant.
Journal: Frontiers in oncology
Published: July 01, 2020
Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
Journal: Cancer science
Published: February 27, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026